New drug enters first human tests for rare Muscle-Weakening disease
NCT ID NCT07354724
Summary
This is the first study in people to test the safety and side effects of a new drug called DNL952 for adults with late-onset Pompe disease, a rare genetic disorder that weakens muscles. The main goal is to see how different doses are tolerated and how the drug moves through the body. The study will enroll about 32 adults who can walk at least 40 meters and have specific lung function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATE-ONSET POMPE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.